OncoMatch/Clinical Trials/NCT07470853
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Is NCT07470853 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including HWK-016, MUCIN-16-targeted ADC and Bevacizumab for proc.
Treatment: HWK-016, MUCIN-16-targeted ADC · Bevacizumab — HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Lab requirements
Cardiac function
Significant cardiovascular disease; QTcF ≥ 470 ms
Significant cardiovascular disease; Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arkansas - Winthrop P. Rockefeller Cancer Institute · Little Rock, Arkansas
- START - Los Angeles · Los Angeles, California
- SCRI - Florida Cancer Specialists · Sarasota, Florida
- St. Francis Medical Center (OSF Healthcare) · Peoria, Illinois
- Karmanos Cancer Center · Detroit, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07470853 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages